Biohaven announces ocd proof of concept phase 2/3 study results and program update

Biohaven announces obsessive-compulsive disorder (ocd) proof of concept phase 2/3 study results and program update.biohaven pharmaceutical - troriluzole was well tolerated with a safety profile consistent with past clinical trial experience.biohaven - plans to advance troriluzole to a full phase 3 development program in ocd, with a larger sample size and addition of a higher-dose arm.biohaven pharmaceutical - troriluzole p-value in proof of concept study did not reach statistical significance at primary y-bocs endpoint at week 12.biohaven pharmaceutical - will have end of phase 2 meeting with fda & plan to initiate an pivotal phase 3 study of two doses of troriluzole versus placebo.
BHVN Ratings Summary
BHVN Quant Ranking